Insulet Corporation (NASDAQ:PODD) is included in our list of the 15 Stocks Set to Explode in the Next 3 Years.
A dose bottle of the medication is in the medical tech’s hand
As of April 6, 2026, over 90% of covering analysts maintain their bullish ratings on Insulet Corporation (NASDAQ:PODD), demonstrating strong Wall Street sentiment. The $360.00 consensus price target implies an upside of over 75%. Amid broader industry headwinds, the stock is down over 11% so far in 2026.
However, on April 2, 2026, Insulet Corporation (NASDAQ:PODD)’s shares hit a new 52-week low of $202.44, down more than 16% from a year earlier, while the medical devices industry as a whole recorded a downtick of over 4%.
Amid that weak share performance, Insulet Corporation (NASDAQ:PODD) named Mike Panos executive vice president and chief commercial officer on March 30, 2026, with immediate effect. This was done in an effort to improve commercial performance in the face of growing automated insulin delivery system usage.
As Omnipod use grows worldwide due to clinical results, innovation, and the increasing adoption of automated insulin delivery as a standard of care, Insulet Corporation (NASDAQ:PODD)’s management stated that the leadership change supports its growth opportunities in both type 1 and type 2 diabetes.
Ashley McEvoy, Insulet President and Chief Executive Officer, commented:
“We have a significant growth opportunity in front of us, driven by strong clinical outcomes, customer-centric innovation, and expanding global adoption of automated insulin delivery as the standard of care in both type 1 and type 2 diabetes. We are implementing thoughtful strategies to strengthen our capabilities and structure to capture this opportunity and are thrilled to welcome Mike to Insulet. His expertise in building high-performing sales organizations and driving execution excellence will help elevate our commercial capabilities as we accelerate our growth.”
Insulet Corporation (NASDAQ:PODD) is a medical device company that designs, manufactures, and sells the Omnipod insulin management system, a tubeless, wearable insulin pump that helps people with diabetes simplify and personalize their insulin delivery.
While we acknowledge the risk and potential of PODD as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than PODD and that has 10,000% upside potential, check out our report about this cheapest AI stock.
READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.
Disclosure: None. Follow Insider Monkey on Google News.
